Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Merck & Co (NY: MRK)
72.35 USD  +0.14 (+0.19%)
Official Closing Price  /  Updated: 6:30 PM EDT, Oct 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 14,513,300
Open 72.30
Bid (Size) 72.06 (1)
Ask (Size) 72.50 (1)
Prev. Close 72.21
Today's Range 71.94 - 72.66
52wk Range 52.83 - 72.89
Shares Outstanding 2,690,303,898
Dividend Yield 2.64%
Performance
YTD
+28.69%
+28.69%
1 Month
+1.76%
+1.76%
3 Month
+15.41%
+15.41%
6 Month
+20.08%
+20.08%
1 Year
+14.12%
+14.12%
Top News
More News
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Ca
SOLO-1 Phase 3 Trial - LYNPARZA Maintenance Therapy Cut Risk of Disease Progression or Death by 70 Percent in Select Ovarian Cancer Patients Read More
from Business Wire News Releases
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Read More
from Business Wire News Releases
More News
Read More
Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
from Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or
from Business Wire News Releases
Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer
from Business Wire News Releases
Merck KGaA says might strike partnership deal this year
category companyNews
from Reuters: Company News
AstraZeneca's Lynparza shown to put brakes on ovarian cancer
category companyNews
from Reuters: Company News
Roche takes on Loxo, Bayer in gene-defined cancer class
category companyNews
from Reuters: Company News
UPDATE 1-Roche scores win in slowing aggressive type of breast cancer
category companyNews
from Reuters: Company News
CORRECTED-Roche's Tecentriq boosts survival in triple-negative breast cancer
category companyNews
from Reuters: Company News
Roche's Tecentriq boosts survival in triple-negative breast cancer
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.